Browsing by title
Now showing items 5796-5815 of 5853
-
Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.
(2019-01)Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically approximately 70% of patients with a complete clinical response to surgery and adjuvant chemotherapy will relapse and die of the ... -
Warthin Tumor-Like Mucoepidermoid Carcinoma.
(SAGE PUBLICATIONS INC, 2018-02-01)Mucoepidermoid carcinoma (MEC) shows a wide morphologic spectrum, including epithelium with oncocytic or squamous metaplastic changes overlying a prominent cystic architecture, as well as tumor-associated lymphoid tissue. ... -
WASp modulates RPA function on single-stranded DNA in response to replication stress and DNA damage.
(NATURE PORTFOLIO, 2022-06-29)Perturbation in the replication-stress response (RSR) and DNA-damage response (DDR) causes genomic instability. Genomic instability occurs in Wiskott-Aldrich syndrome (WAS), a primary immunodeficiency disorder, yet the ... -
Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer.
(2018-01)Purpose of Review:Pathological complete response is seen in approximately one fifth of rectal cancer patients following neoadjuvant chemoradiation. Since these patients have excellent oncological outcomes, there has been ... -
WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer.
(2020-11-21)Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer that lacks the oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, making it difficult to target ... -
WDR5, BRCA1, and BARD1 Co-regulate the DNA Damage Response and Modulate the Mesenchymal-to-Epithelial Transition during Early Reprogramming.
(CELL PRESS, 2019-04-09)Differentiated cells are epigenetically stable, but can be reprogrammed to pluripotency by expression of the OSKM transcription factors. Despite significant effort, relatively little is known about the cellular requirements ... -
Weaver Syndrome and EZH2 Mutations: Clarifying the Clinical Phenotype
(2013-12-01)Weaver syndrome, first described in 1974, is characterized by tall stature, a typical facial appearance, and variable intellectual disability. In 2011, mutations in the histone methyltransferase, EZH2, were shown to cause ... -
Weekly COVID-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic.
(ROYAL SOC, 2020-06-24)The COVID-19 epidemic can probably be ended and normal life restored, perhaps quite quickly, by weekly SARS-CoV-2 RNA testing together with household quarantine and systematic contact tracing. Isolated outbreaks could then ... -
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
(ELSEVIER SCIENCE INC, 2022-07-01)BACKGROUND: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and ... -
Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
(FUTURE MEDICINE LTD, 2016-06-01) -
What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK
(Springer Science and Business Media LLC, 2018-12-01) -
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
(ELSEVIER, 2022-02-17)Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, ... -
What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit.
(BMJ PUBLISHING GROUP, 2022-11-28)INTRODUCTION: Novel therapies such as small protein molecule inhibitors and immunotherapies are tested in early phase trials before moving to later phase trials and ultimately standard practice. A key aim of these clinical ... -
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
(ELSEVIER, 2018-05-01)BACKGROUND: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone ... -
What Matters to Us: Impact of Telemedicine During the Pandemic in the Care of Patients With Sarcoma Across Scotland.
Purpose In Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five specialist centers. Many patients are required to travel long distances to access specialist care. The COVID-19 ... -
What Resources do NHS Commissioning Organisations Use to Support Antimicrobial Stewardship in Primary Care in England?
(MDPI AG, 2020-04-02)Professional education and public engagement are fundamental components of any antimicrobial stewardship (AMS) strategy. The National Institute for Health and Care Excellence (NICE), Public Health England (PHE), Health ... -
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.
Background All risk stratification strategies in cancer overlook a spectrum of disease. The Prostate MR Imaging Study (PROMIS) provides a unique opportunity to explore cancers that are overlooked by multiparametric magnetic ... -
What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century.
(BRITISH INST RADIOLOGY, 2020-11-01)Whole-body MRI (WB-MRI) has evolved since its first introduction in the 1970s as an imaging technique to detect and survey disease across multiple sites and organ systems in the body. The development of diffusion-weighted ... -
When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers.
(2017-07)Although the incidence of prostate cancer is rising due to PSA screening and increased life expectancy, the metastatic potential of low-grade, organ-confined disease remains low. An increasing number of studies suggest ...
